November 29, 2016
(Reuters) – Scientists are taking the battle to prevent HIV to the next level with large-scale trials set to start using injections to protect vulnerable groups such as gay men and women in Africa for at least two months. Further down the road, the hope is to produce matchstick-sized implants containing slow-release drugs – similar to existing under-the-skin contraceptive devices – that could offer year-long protection. Companies with drugs involved include GlaxoSmithKline, Gilead Sciences and Merck.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.